+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

HPV Associated Disorders Market by Product (Diagnostics, Therapeutics, Vaccines), Indication (Prevention, Screening, Treatment), End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5674352
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior executives seeking actionable intelligence on the HPV Associated Disorders Market will find this report essential for understanding evolving clinical dynamics, technology innovation, and regulatory shifts driving growth. Thorough segmentation—by product, indication, end user, and geography—ensures tailored strategic insights for leadership.

Market Snapshot: HPV Associated Disorders Market Overview

The HPV Associated Disorders Market grew from USD 9.84 billion in 2024 to USD 10.46 billion in 2025. It is expected to continue growing at a CAGR of 6.19%, reaching USD 14.12 billion by 2030. This robust progress highlights increasing global focus on HPV screening, prevention, and therapeutic innovation across multiple healthcare ecosystems. Market expansion is propelled by advances in diagnostics, vaccination, and treatment, as well as regional efforts to address clinical and supply chain challenges.

Scope & Segmentation

This report provides a comprehensive breakdown of the HPV Associated Disorders Market, offering invaluable clarity for decision-makers navigating complex product categories and global landscapes.

  • Product: Diagnostics (including HPV DNA testing, hybrid capture, PCR-based assays, Pap tests with both conventional and liquid-based cytology), Therapeutics (such as chemotherapy, radiotherapy, cryotherapy, excision, laser, topical agents like imiquimod and podophyllotoxin), and Vaccines (bivalent, quadrivalent, nonavalent; branded portfolios from leading manufacturers).
  • Indication: Prevention, screening, and treatment solutions are analyzed, capturing the full continuum from primary prophylaxis to disease management.
  • End User: Ambulatory surgical centers, general practitioner clinics, specialist clinics, diagnostic laboratories, and both private and public hospital networks capture varied clinical deployment environments.
  • Distribution Channel: Addresses direct procurement, hospital pharmacy, online retail, and retail pharmacy for insight into evolving purchasing behaviors and logistics.
  • Region: Global analysis covers Americas (with U.S. state-level detail), Europe, Middle East & Africa, and Asia-Pacific, reflecting disparate healthcare, regulatory, and access realities.
  • Companies Profiled: Market analyses include key players such as Merck & Co., GlaxoSmithKline plc, Roche Diagnostics International, Hologic Inc., QIAGEN, Abbott Laboratories, Becton Dickinson, Danaher, Thermo Fisher, and PerkinElmer.

Key Takeaways for Senior Leaders

  • Innovative diagnostics, including PCR-based and hybrid technologies, are shaping detection paradigms and driving precision in clinical workflows.
  • Emerging vaccines and personalized therapeutic modalities offer new avenues for addressing persistent gaps in prevention and treatment effectiveness.
  • Regional approaches, particularly in North America and Asia-Pacific, leverage public-private partnerships and digital health to expand coverage and real-world impact.
  • Collaboration between industry, public health agencies, and academic bodies is facilitating multi-stakeholder pathways—accelerating adoption of new protocols and supporting reimbursement models linked to outcomes.
  • Integrated supply chain management and resilience planning are increasingly critical, especially in adapting to geopolitical influences and tariff developments.

Tariff Impact

Recent U.S. tariff changes in 2025 have complicated sourcing for diagnostics reagents and vaccine materials. Market participants are mitigating risks with renewed regional sourcing, supplier diversification, and increased stockpiling. Production and quality assurance processes have been modified, affecting timelines for product launches and compliance. The result is a stronger focus on local production and agile supply chain governance to secure ongoing access to vital interventions.

Methodology & Data Sources

Report findings are derived from a mixed-methods approach. Primary research includes interviews with clinicians and senior industry figures; secondary research utilizes scientific literature, regulatory publications, and agency data. Extensive triangulation ensures objective validation of diagnostic trends, technology adoption, and supply chain variables.

Why This Report Matters

  • Empowers executive-level planning through rigorous coverage of clinical, operational, and policy drivers shaping the HPV Associated Disorders Market.
  • Provides actionable segmentation and channel strategies, enabling targeted investment and risk/reward optimization.
  • Supports decision-makers in responding proactively to supply chain risk and policy shifts, securing sustainable patient access and operational continuity.

Conclusion

Forward-thinking leaders will benefit from this report’s synthesis of segmentation, innovation, and operational challenges. Strategic use of these insights will help organizations maximize value, enhance clinical outcomes, and adapt to regional and global shifts in the HPV Associated Disorders Market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of next-generation HPV DNA testing assays for early detection of high-risk HPV strains
5.2. Expansion of HPV vaccination programs to include broader age groups and gender populations
5.3. Integration of telehealth platforms in cervical screening and HPV vaccination outreach initiatives
5.4. Growth of personalized immunotherapy treatments targeting HPV-related precancerous lesions and cancers
5.5. Increasing regulatory approvals for nonavalent and next-generation HPV vaccines affecting market access
5.6. Development of self-sampling HPV testing kits to improve screening rates among under-screened populations
5.7. Emergence of digital health solutions for monitoring post-treatment recurrence in HPV associated cancers
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. HPV Associated Disorders Market, by Product
8.1. Introduction
8.2. Diagnostics
8.2.1. HPV DNA Test
8.2.1.1. Hybrid Capture
8.2.1.2. PCR Based
8.2.2. Pap Test
8.2.2.1. Conventional Cytology
8.2.2.2. Liquid Based Cytology
8.3. Therapeutics
8.3.1. Cancer Treatments
8.3.1.1. Chemotherapy
8.3.1.2. Radiotherapy
8.3.2. Surgical Treatments
8.3.2.1. Cryotherapy
8.3.2.2. Excision
8.3.2.3. Laser Therapy
8.3.3. Topical Treatments
8.3.3.1. Imiquimod
8.3.3.2. Podophyllotoxin
8.4. Vaccines
8.4.1. Bivalent
8.4.1.1. GlaxoSmithKline
8.4.2. Nonavalent
8.4.2.1. Merck
8.4.3. Quadrivalent
8.4.3.1. Merck
9. HPV Associated Disorders Market, by Indication
9.1. Introduction
9.2. Prevention
9.3. Screening
9.4. Treatment
10. HPV Associated Disorders Market, by End User
10.1. Introduction
10.2. Ambulatory Surgical Centers
10.3. Clinics
10.3.1. General Practitioner Clinics
10.3.2. Specialist Clinics
10.4. Diagnostic Laboratories
10.5. Hospitals
10.5.1. Private Hospitals
10.5.2. Public Hospitals
11. HPV Associated Disorders Market, by Distribution Channel
11.1. Introduction
11.2. Direct Procurement
11.3. Hospital Pharmacy
11.4. Online Retail
11.5. Retail Pharmacy
12. Americas HPV Associated Disorders Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa HPV Associated Disorders Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific HPV Associated Disorders Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Merck & Co., Inc.
15.3.2. GlaxoSmithKline plc
15.3.3. Roche Diagnostics International AG
15.3.4. Hologic, Inc.
15.3.5. QIAGEN N.V.
15.3.6. Abbott Laboratories
15.3.7. Becton, Dickinson and Company
15.3.8. Danaher Corporation
15.3.9. Thermo Fisher Scientific Inc.
15.3.10. PerkinElmer, Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. HPV ASSOCIATED DISORDERS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
FIGURE 6. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. HPV ASSOCIATED DISORDERS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. HPV ASSOCIATED DISORDERS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. HPV ASSOCIATED DISORDERS MARKET: RESEARCHAI
FIGURE 24. HPV ASSOCIATED DISORDERS MARKET: RESEARCHSTATISTICS
FIGURE 25. HPV ASSOCIATED DISORDERS MARKET: RESEARCHCONTACTS
FIGURE 26. HPV ASSOCIATED DISORDERS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. HPV ASSOCIATED DISORDERS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY HPV DNA TEST, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY HPV DNA TEST, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY HYBRID CAPTURE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY HYBRID CAPTURE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY PCR BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY PCR BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY HPV DNA TEST, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY HPV DNA TEST, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY PAP TEST, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY PAP TEST, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY CONVENTIONAL CYTOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY CONVENTIONAL CYTOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY LIQUID BASED CYTOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY LIQUID BASED CYTOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY PAP TEST, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY PAP TEST, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY CANCER TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY CANCER TREATMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY CANCER TREATMENTS, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY CANCER TREATMENTS, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY CRYOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY CRYOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY EXCISION, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY EXCISION, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY LASER THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY TOPICAL TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY TOPICAL TREATMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY IMIQUIMOD, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY IMIQUIMOD, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY PODOPHYLLOTOXIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY PODOPHYLLOTOXIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY BIVALENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY BIVALENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY GLAXOSMITHKLINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY GLAXOSMITHKLINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY BIVALENT, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY BIVALENT, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY NONAVALENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY NONAVALENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY MERCK, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY MERCK, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY NONAVALENT, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY NONAVALENT, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY QUADRIVALENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY QUADRIVALENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY MERCK, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY MERCK, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY QUADRIVALENT, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY QUADRIVALENT, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY PREVENTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY PREVENTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY SCREENING, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY SCREENING, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY TREATMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY TREATMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY GENERAL PRACTITIONER CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY GENERAL PRACTITIONER CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DIRECT PROCUREMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DIRECT PROCUREMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL HPV ASSOCIATED DISORDERS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY HPV DNA TEST, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY HPV DNA TEST, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY PAP TEST, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY PAP TEST, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY CANCER TREATMENTS, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY CANCER TREATMENTS, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY BIVALENT, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY BIVALENT, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY NONAVALENT, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY NONAVALENT, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY QUADRIVALENT, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY QUADRIVALENT, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS HPV ASSOCIATED DISORDERS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 159. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 160. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 161. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 162. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 163. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY HPV DNA TEST, 2018-2024 (USD MILLION)
TABLE 164. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY HPV DNA TEST, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY PAP TEST, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY PAP TEST, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY CANCER TREATMENTS, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY CANCER TREATMENTS, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY BIVALENT, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY BIVALENT, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY NONAVALENT, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY NONAVALENT, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY QUADRIVALENT, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY QUADRIVALENT, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES HPV ASSOCIATED DISORDERS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 195. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 196. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 197. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 198. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 199. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY HPV DNA TEST, 2018-2024 (USD MILLION)
TABLE 200. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY HPV DNA TEST, 2025-2030 (USD MILLION)
TABLE 201. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY PAP TEST, 2018-2024 (USD MILLION)
TABLE 202. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY PAP TEST, 2025-2030 (USD MILLION)
TABLE 203. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 204. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 205. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY CANCER TREATMENTS, 2018-2024 (USD MILLION)
TABLE 206. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY CANCER TREATMENTS, 2025-2030 (USD MILLION)
TABLE 207. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 208. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 209. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 210. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 211. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 212. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 213. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY BIVALENT, 2018-2024 (USD MILLION)
TABLE 214. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY BIVALENT, 2025-2030 (USD MILLION)
TABLE 215. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY NONAVALENT, 2018-2024 (USD MILLION)
TABLE 216. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY NONAVALENT, 2025-2030 (USD MILLION)
TABLE 217. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY QUADRIVALENT, 2018-2024 (USD MILLION)
TABLE 218. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY QUADRIVALENT, 2025-2030 (USD MILLION)
TABLE 219. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 220. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 221. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 222. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 223. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 224. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 225. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 226. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 227. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. CANADA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 230. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 231. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 232. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 233. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY HPV DNA TEST, 2018-2024 (USD MILLION)
TABLE 234. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY HPV DNA TEST, 2025-2030 (USD MILLION)
TABLE 235. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY PAP TEST, 2018-2024 (USD MILLION)
TABLE 236. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY PAP TEST, 2025-2030 (USD MILLION)
TABLE 237. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 238. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 239. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY CANCER TREATMENTS, 2018-2024 (USD MILLION)
TABLE 240. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY CANCER TREATMENTS, 2025-2030 (USD MILLION)
TABLE 241. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 242. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 243. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 244. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 245. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 246. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 247. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY BIVALENT, 2018-2024 (USD MILLION)
TABLE 248. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY BIVALENT, 2025-2030 (USD MILLION)
TABLE 249. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY NONAVALENT, 2018-2024 (USD MILLION)
TABLE 250. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY NONAVALENT, 2025-2030 (USD MILLION)
TABLE 251. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY QUADRIVALENT, 2018-2024 (USD MILLION)
TABLE 252. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY QUADRIVALENT, 2025-2030 (USD MILLION)
TABLE 253. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 254. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 255. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 258. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 259. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 260. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 261. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. MEXICO HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 264. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 265. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 266. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 267. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY HPV DNA TEST, 2018-2024 (USD MILLION)
TABLE 268. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY HPV DNA TEST, 2025-2030 (USD MILLION)
TABLE 269. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY PAP TEST, 2018-2024 (USD MILLION)
TABLE 270. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY PAP TEST, 2025-2030 (USD MILLION)
TABLE 271. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 272. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 273. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY CANCER TREATMENTS, 2018-2024 (USD MILLION)
TABLE 274. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY CANCER TREATMENTS, 2025-2030 (USD MILLION)
TABLE 275. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 276. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 277. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 278. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 279. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 280. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 281. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY BIVALENT, 2018-2024 (USD MILLION)
TABLE 282. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY BIVALENT, 2025-2030 (USD MILLION)
TABLE 283. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY NONAVALENT, 2018-2024 (USD MILLION)
TABLE 284. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY NONAVALENT, 2025-2030 (USD MILLION)
TABLE 285. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY QUADRIVALENT, 2018-2024 (USD MILLION)
TABLE 286. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY QUADRIVALENT, 2025-2030 (USD MILLION)
TABLE 287. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 288. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 289. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 290. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 291. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 292. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 293. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 294. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 295. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 296. BRAZIL HPV ASSOCIATED DISORDERS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 297. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 298. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 299. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
TABLE 300. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY DIAGNOSTICS, 2025-2030 (USD MILLION)
TABLE 301. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY HPV DNA TEST, 2018-2024 (USD MILLION)
TABLE 302. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY HPV DNA TEST, 2025-2030 (USD MILLION)
TABLE 303. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY PAP TEST, 2018-2024 (USD MILLION)
TABLE 304. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY PAP TEST, 2025-2030 (USD MILLION)
TABLE 305. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPEUTICS, 2018-2024 (USD MILLION)
TABLE 306. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY THERAPEUTICS, 2025-2030 (USD MILLION)
TABLE 307. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY CANCER TREATMENTS, 2018-2024 (USD MILLION)
TABLE 308. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY CANCER TREATMENTS, 2025-2030 (USD MILLION)
TABLE 309. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 310. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY SURGICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 311. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY TOPICAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 312. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY TOPICAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 313. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 314. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 315. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY BIVALENT, 2018-2024 (USD MILLION)
TABLE 316. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY BIVALENT, 2025-2030 (USD MILLION)
TABLE 317. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY NONAVALENT, 2018-2024 (USD MILLION)
TABLE 318. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY NONAVALENT, 2025-2030 (USD MILLION)
TABLE 319. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY QUADRIVALENT, 2018-2024 (USD MILLION)
TABLE 320. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY QUADRIVALENT, 2025-2030 (USD MILLION)
TABLE 321. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 322. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 323. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 324. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 325. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 326. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 327. ARGENTINA HPV ASSOCIATED DISORDERS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 328.

Samples

Loading
LOADING...

Companies Mentioned

  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Roche Diagnostics International AG
  • Hologic, Inc.
  • QIAGEN N.V.
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • PerkinElmer, Inc.

Table Information